GlassScriptPhysician profile
Thomas Joseph Fox
NPI 1588653273
$3,320.96
in general payments reported to CMS, 2019-2025
36 companies · $22.36 in 2025
The $22.36 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,512 · 2020: $399 · 2021: $128 · 2022: $193 · 2023: $33.92 · 2024: $31.66 · 2025: $22.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $87.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $87.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $355.01 | 2019-2021 | |
| Ucb, INC. | $344.86 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $320.74 | 2019-2022 | |
| Genzyme Corporation | $306.65 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $186.50 | 2019 | |
| Emd Serono, INC. | $185.46 | 2019-2022 | |
| Biogen, INC. | $184.51 | 2019-2020 | |
| Abbvie INC. | $173.86 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $136.71 | 2019 | |
| Amgen INC. | $132.61 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $125.17 | 2019-2021 | |
| Genentech USA, INC. | $97.30 | 2019-2023 | Ocrevus, Enspryng |
| Eisai INC. | $73.59 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $56.33 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $55.70 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $54.66 | 2019 | |
| Allergan, INC. | $48.75 | 2019 | |
| Mdd US Operations, LLC | $48.34 | 2019-2025 | Gocovri |
| Mallinckrodt Enterprises LLC | $38.41 | 2019 | |
| Bausch Health US, LLC | $36.38 | 2019 | |
| Merz North America, INC. | $34.53 | 2019 | |
| Lundbeck LLC | $33.86 | 2019 | |
| Tanabe Pharma America, INC. | $33.46 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $29.76 | 2020 | |
| Grifols USA, LLC | $28.92 | 2019 | |
| Grt US Holding, INC. | $26.09 | 2022 | |
| Strongbridge US INC. | $25.02 | 2019 | |
| Acadia Pharmaceuticals INC | $24.86 | 2019 | |
| Csl Behring | $21.07 | 2019 | |
| Upsher-Smith Laboratories LLC | $19.32 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.61 | 2022 | |
| Neurocrine Biosciences, INC. | $15.06 | 2019 | |
| Promius Pharma LLC | $13.58 | 2019 | |
| Horizon Therapeutics Plc | $13.16 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.96 | 2021 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.